Personalized Repetitive Transcranial Magnetic Stimulation for Primary Progressive Aphasia.


Journal

Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863

Informations de publication

Date de publication:
2021
Historique:
pubmed: 7 9 2021
medline: 5 1 2022
entrez: 6 9 2021
Statut: ppublish

Résumé

Primary progressive aphasia (PPA) is a neurodegenerative syndrome for which no effective treatment is available. We aimed to assess the effect of repetitive transcranial magnetic stimulation (rTMS), using personalized targeting. We conducted a randomized, double-blind, pilot study of patients with PPA receiving rTMS, with a subgroup of patients receiving active- versus control-site rTMS in a cross-over design. Target for active TMS varied among the cases and was determined during a pre-treatment phase from a list of potential regions. The primary outcome was changes in spontaneous speech (word count). Secondary outcomes included changes in other language tasks, global cognition, global impression of change, neuropsychiatric symptoms, and brain metabolism using FDG-PET. Twenty patients with PPA were enrolled (14 with nonfluent and 6 with semantic variant PPA). For statistical analyses, data for the two variants were combined. Compared to the control group (n = 7), the group receiving active-site rTMS (n = 20) showed improvements in spontaneous speech, other language tasks, patient and caregiver global impression of change, apathy, and depression. This group also showed improvement or stabilization of results obtained in the baseline examination. Increased metabolism was observed in several brain regions after the therapy, particularly in the left frontal and parieto-temporal lobes and in the precuneus and posterior cingulate bilaterally. We found an improvement in language, patient and caregiver perception of change, apathy, and depression using high frequency rTMS. The increase of regional brain metabolism suggests enhancement of synaptic activity with the treatment. NCT03580954 (https://clinicaltrials.gov/ct2/show/NCT03580954).

Sections du résumé

BACKGROUND
Primary progressive aphasia (PPA) is a neurodegenerative syndrome for which no effective treatment is available.
OBJECTIVE
We aimed to assess the effect of repetitive transcranial magnetic stimulation (rTMS), using personalized targeting.
METHODS
We conducted a randomized, double-blind, pilot study of patients with PPA receiving rTMS, with a subgroup of patients receiving active- versus control-site rTMS in a cross-over design. Target for active TMS varied among the cases and was determined during a pre-treatment phase from a list of potential regions. The primary outcome was changes in spontaneous speech (word count). Secondary outcomes included changes in other language tasks, global cognition, global impression of change, neuropsychiatric symptoms, and brain metabolism using FDG-PET.
RESULTS
Twenty patients with PPA were enrolled (14 with nonfluent and 6 with semantic variant PPA). For statistical analyses, data for the two variants were combined. Compared to the control group (n = 7), the group receiving active-site rTMS (n = 20) showed improvements in spontaneous speech, other language tasks, patient and caregiver global impression of change, apathy, and depression. This group also showed improvement or stabilization of results obtained in the baseline examination. Increased metabolism was observed in several brain regions after the therapy, particularly in the left frontal and parieto-temporal lobes and in the precuneus and posterior cingulate bilaterally.
CONCLUSION
We found an improvement in language, patient and caregiver perception of change, apathy, and depression using high frequency rTMS. The increase of regional brain metabolism suggests enhancement of synaptic activity with the treatment.
TRIAL REGISTRATION
NCT03580954 (https://clinicaltrials.gov/ct2/show/NCT03580954).

Identifiants

pubmed: 34487043
pii: JAD210566
doi: 10.3233/JAD-210566
doi:

Banques de données

ClinicalTrials.gov
['NCT03580954']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

151-167

Auteurs

Vanesa Pytel (V)

Department of Neurology, Hospital Clínico SanCarlos, San Carlos Health Research Institute (IdISSC), UniversidadComplutense de Madrid, Madrid, Spain.

María Nieves Cabrera-Martín (MN)

Departmentof Nuclear Medicine, Hospital Clínico San Carlos, San CarlosHealth Research Institute (IdISSC), Universidad Complutense deMadrid, Madrid, Spain.

Alfonso Delgado-Álvarez (A)

Department of Neurology, Hospital Clínico SanCarlos, San Carlos Health Research Institute (IdISSC), UniversidadComplutense de Madrid, Madrid, Spain.

José Luis Ayala (JL)

Department of ComputerArchitecture and Automation, Universidad Complutense de Madrid, Madrid, Spain.

Paloma Balugo (P)

Department of ClinicalNeurophysiology, Hospital Clínico San Carlos, San Carlos HealthResearch Institute (IdISSC), Universidad Complutense de Madrid, Madrid, Spain.

Cristina Delgado-Alonso (C)

Department of Neurology, Hospital Clínico SanCarlos, San Carlos Health Research Institute (IdISSC), UniversidadComplutense de Madrid, Madrid, Spain.

Miguel Yus (M)

Department of Radiology, HospitalClínico San Carlos, San Carlos Health Research Institute(IdISSC), Universidad Complutense de Madrid, Madrid, Spain.

María Teresa Carreras (MT)

Department of Neurology, Hospital Universitario LaPrincesa, La Princesa Health Research Institute, Madrid, Spain.

José Luis Carreras (JL)

Departmentof Nuclear Medicine, Hospital Clínico San Carlos, San CarlosHealth Research Institute (IdISSC), Universidad Complutense deMadrid, Madrid, Spain.

Jorge Matías-Guiu (J)

Department of Neurology, Hospital Clínico SanCarlos, San Carlos Health Research Institute (IdISSC), UniversidadComplutense de Madrid, Madrid, Spain.

Jordi A Matías-Guiu (JA)

Department of Neurology, Hospital Clínico SanCarlos, San Carlos Health Research Institute (IdISSC), UniversidadComplutense de Madrid, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH